Skip to content
OpenCapital
Get started

Ocular Therapeutix OCUL Shares (Diluted)

Shares (Diluted) at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
107.7M-3.1%
Bausch + Lomb logo
Bausch + LombBLCO
355.2M+0.7%
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
43M+9.2%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
61.9M+17.3%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
100.6M+4.5%
PBH
Prestige Consumer HealthcarePBH
48.7M-2.7%

Other financials

Income statement

See full
Revenue$10.8M+0.8%
Gross profit$9.5M+0.2%
Operating income-$93.3M-46.0%
Net income-$88.6M-38.3%
EPS (diluted)-$0.40-5.3%

Balance sheet

See full
Cash & equivalents$666.7M+90.7%
Total debt$79.5M+4.2%
Total equity$581.6M+119%
Total assets$732.5M+80.5%

Cash flow

See full
Operating cash flow-$66.0M-47.7%
CapEx$4.7M+141%
Free cash flow-$70.7M-51.6%

Valuation

See full
Market cap$2.21B+58.2%
Enterprise value$1.63B+40.8%
P/S42.6×+19.1×

Profitability

See full
Gross margin87.2%-3.4pp
Operating margin-575.4%+1,233pp
Net margin-558.2%+1,493pp
FCF margin-463%+2,860pp

Returns & leverage

See full
Return on equity-68.6%+17.0pp
Debt / equity0.1×-0.2×
Current ratio14.8×+4.6×

Where this comes from

Reported directly by Ocular Therapeutix in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The official record: Ocular Therapeutix’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ocular Therapeutix's shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ocular Therapeutix's shares (diluted)?
Ocular Therapeutix (OCUL) reported shares (diluted) of 224.1M in Q1 2026.
How has Ocular Therapeutix's shares (diluted) changed year-over-year?
Ocular Therapeutix's shares (diluted) increased by 32.3% year-over-year, from 169.4M to 224.1M.
What is the long-term trend for Ocular Therapeutix's shares (diluted)?
Over 4 years (2021 to 2025), Ocular Therapeutix's shares (diluted) has grown at a 20.6% compound annual growth rate (CAGR), from 336.9M to 713.2M.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.